HENDERSON, NV / ACCESSWIRE / January 30, 2019 / The biotechnology sector has been roaring back strong in 2019. There a few companies that we think you should be researching right now.
One company who's on the verge of a major breakthrough, BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue. The stock is still relatively unknown, however, with the global obesity treatment market expected to reach $15.6 billion by 2024 you can bet investors will be very interested in this company when they learn about it. Get a jumpstart on the crowd by researching BRTX today.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), 22nd Century Group, Inc. (XXII), GW Pharmaceuticals plc (GWPH), INSYS Therapeutics, Inc. (INSY) and Zynerba Pharmaceuticals, Inc. (ZYNE).
According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.
One of the more novel approaches to fighting this obesity epidemic is being developed by BioRestorative Therapies, Inc. (BRTX) (Market Cap: $7.669M, Share Price: $0.60), a life sciences company focused on stem cell-based therapies, developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue (''BAT''). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
22nd Century Group, Inc. (XXII) (Market Cap: $271.194M, Share Price: $2.18) submitted a Modified Risk Tobacco Product (MRTP) application with the U.S. Food and Drug Administration (FDA) for the Company's Very Low Nicotine Content (VLNC) cigarettes. 22nd Century's proposed VLNTM cigarettes, the subject of the MRTP application, are made with the Company's proprietary VLNTM tobacco and, as a result, contain very low levels of nicotine.
GW Pharmaceuticals plc (GWPH) (Market Cap: $4.395B, Share Price: $135.87), a biopharmaceutical company focused on discovering, developing and commercializing treatment options from its proprietary cannabinoid platform, recently presented at the JP Morgan healthcare conference.
INSYS Therapeutics, Inc. (INSY) (Market Cap: $262.172M, Share Price: $3.53) announced positive results from its dose-finding pharmacokinetic ("PK") study —INS015-18-124—evaluating proprietary formulation of epinephrine nasal spray for treating anaphylaxis, an acute, life-threatening allergic reaction. Data from the study showed that the candidate has a similar PK profile with Mylan's MYL EpiPen as well as Par Pharmaceuticals' Adrenalin (epinephrine injection).
Zynerba Pharmaceuticals, Inc. (ZYNE) (Market Cap: $84.785M, Share Price: $4.81) released 12-month clinical data that describes the lifelong impact of ZYN002 on developmental and responsive symptoms of Fragile X syndrome. In a poster for the presentation in the 57th annual meeting, Professor Steven Siegel gives the presentation of the 12-month data of the second phase of the clinical trial of […] The post Zynerba Gives Clinical Update, Lifelong Impact of ZYN002 appeared first on Market Exclusive.
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $25,000 cash for February services and expects to be compensated an additional $25,000 for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC